FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3158736337> ?p ?o ?g. }

• W3158736337 abstract "To compare the efficacy and safety between pyrotinib (Pyr) and trastuzumab emtansine (T-DM1) in pre-treated human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) patients.A comprehensive literature search of the PubMed, EMBASE, and Web of Science was performed in August 2020. Randomized clinical trials comparing the efficacy and safety between different anti-HER2 regimens in patients pre-treated with trastuzumab (Tra) and a taxane in metastatic settings (≤second-line treatment) were included. A fixed effects network meta-analysis based on the Bayesian inferential framework was conducted for progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and grade ≥3 adverse events (AEs). Values of surface under cumulative ranking probability curve (SUCRA) were calculated to offer a ranking of all regimens.Twelve studies with 4,353 subjects were identified. Nine regimens were included into the network: T-DM1, lapatinib-capecitabine (Lap-Cap), Tra-Cap, Cap, neratinib (Ner), pertuzumab (Per)-Tra-Cap, Pyr-Cap, atezolizumab (Ate)-T-DM1, and Ner-Cap. For PFS, Pyr-Cap was more favorable than T-DM1 (hazard ratio, 95% confidence interval: 0.77, 0.70-0.86), Lap-Cap (0.64, 0.59-0.69), Tra-Cap (0.63, 0.56-0.70), Cap (0.50, 0.45-0.56), Ner (0.59, 0.51-0.69), Per-Tra-Cap (0.68, 0.59-0.79), and Ner-Cap (0.72, 0.64-0.81). For OS, Pyr-Cap showed further improvement than Lap-Cap (hazard ratio, 95% confidence interval: 0.71, 0.52-0.99), Cap (0.68, 0.49-0.96), and Ner (0.65, 0.45-0.94). For ORR, Pyr-Cap was significantly superior than Cap (odds ratio, 95% confidence interval: 7.87, 1.22-56.51). No significant difference was observed in grade ≥3 AEs among all the regimens. Pyr-Cap ranked in the highest in PFS, OS, ORR, and grade ≥3 AEs (SUCRA = 99.4, 89.7, 86.4, and 89.3%).These results indicate that Pyr may be more effective than T-DM1 in HER2+ MBC patients pre-treated with Tra and a taxane. However, it may be associated with more grade ≥3 AEs." @default.
• W3158736337 created "2021-05-10" @default.
• W3158736337 creator A5003088149 @default.
• W3158736337 creator A5011307607 @default.
• W3158736337 creator A5020666476 @default.
• W3158736337 creator A5035927781 @default.
• W3158736337 creator A5074012653 @default.
• W3158736337 date "2021-05-03" @default.
• W3158736337 modified "2023-10-16" @default.
• W3158736337 title "Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis" @default.
• W3158736337 cites W1964808503 @default.
• W3158736337 cites W1972806462 @default.
• W3158736337 cites W1984007340 @default.
• W3158736337 cites W2010699829 @default.
• W3158736337 cites W2044702943 @default.
• W3158736337 cites W2098775844 @default.
• W3158736337 cites W2098923148 @default.
• W3158736337 cites W2105536631 @default.
• W3158736337 cites W2109391487 @default.
• W3158736337 cites W2110444464 @default.
• W3158736337 cites W2113144077 @default.
• W3158736337 cites W2115273230 @default.
• W3158736337 cites W2132893003 @default.
• W3158736337 cites W2133531206 @default.
• W3158736337 cites W2134031795 @default.
• W3158736337 cites W2137086207 @default.
• W3158736337 cites W2141393790 @default.
• W3158736337 cites W2149773268 @default.
• W3158736337 cites W2151225337 @default.
• W3158736337 cites W2151262170 @default.
• W3158736337 cites W2159967578 @default.
• W3158736337 cites W2318605753 @default.
• W3158736337 cites W2460584341 @default.
• W3158736337 cites W2560406314 @default.
• W3158736337 cites W2577651608 @default.
• W3158736337 cites W2588681363 @default.
• W3158736337 cites W2609953159 @default.
• W3158736337 cites W2613098450 @default.
• W3158736337 cites W2616329889 @default.
• W3158736337 cites W2616596696 @default.
• W3158736337 cites W2801864212 @default.
• W3158736337 cites W2889646458 @default.
• W3158736337 cites W2897247590 @default.
• W3158736337 cites W2902218997 @default.
• W3158736337 cites W2947964130 @default.
• W3158736337 cites W2969604985 @default.
• W3158736337 cites W2970684805 @default.
• W3158736337 cites W2977267327 @default.
• W3158736337 cites W3007580854 @default.
• W3158736337 cites W3010197652 @default.
• W3158736337 cites W3027694758 @default.
• W3158736337 cites W3028675451 @default.
• W3158736337 cites W3043096450 @default.
• W3158736337 cites W3080520451 @default.
• W3158736337 cites W3116945026 @default.
• W3158736337 cites W3127064904 @default.
• W3158736337 cites W3195411676 @default.
• W3158736337 doi "https://doi.org/10.3389/fonc.2021.608781" @default.
• W3158736337 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8127838" @default.
• W3158736337 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34012912" @default.
• W3158736337 hasPublicationYear "2021" @default.
• W3158736337 type Work @default.
• W3158736337 sameAs 3158736337 @default.
• W3158736337 citedByCount "3" @default.
• W3158736337 countsByYear W31587363372022 @default.
• W3158736337 countsByYear W31587363372023 @default.
• W3158736337 crossrefType "journal-article" @default.
• W3158736337 hasAuthorship W3158736337A5003088149 @default.
• W3158736337 hasAuthorship W3158736337A5011307607 @default.
• W3158736337 hasAuthorship W3158736337A5020666476 @default.
• W3158736337 hasAuthorship W3158736337A5035927781 @default.
• W3158736337 hasAuthorship W3158736337A5074012653 @default.
• W3158736337 hasBestOaLocation W31587363371 @default.
• W3158736337 hasConcept C121608353 @default.
• W3158736337 hasConcept C126322002 @default.
• W3158736337 hasConcept C143998085 @default.
• W3158736337 hasConcept C207103383 @default.
• W3158736337 hasConcept C2775930923 @default.
• W3158736337 hasConcept C2777329042 @default.
• W3158736337 hasConcept C2777511904 @default.
• W3158736337 hasConcept C2777909004 @default.
• W3158736337 hasConcept C2778087150 @default.
• W3158736337 hasConcept C2779786085 @default.
• W3158736337 hasConcept C2781164504 @default.
• W3158736337 hasConcept C44249647 @default.
• W3158736337 hasConcept C526805850 @default.
• W3158736337 hasConcept C530470458 @default.
• W3158736337 hasConcept C71924100 @default.
• W3158736337 hasConceptScore W3158736337C121608353 @default.
• W3158736337 hasConceptScore W3158736337C126322002 @default.
• W3158736337 hasConceptScore W3158736337C143998085 @default.
• W3158736337 hasConceptScore W3158736337C207103383 @default.
• W3158736337 hasConceptScore W3158736337C2775930923 @default.
• W3158736337 hasConceptScore W3158736337C2777329042 @default.
• W3158736337 hasConceptScore W3158736337C2777511904 @default.
• W3158736337 hasConceptScore W3158736337C2777909004 @default.
• W3158736337 hasConceptScore W3158736337C2778087150 @default.
• W3158736337 hasConceptScore W3158736337C2779786085 @default.
• W3158736337 hasConceptScore W3158736337C2781164504 @default.
• W3158736337 hasConceptScore W3158736337C44249647 @default.

• next